Clinical Trial Update: Expanded Access Use of Cemiplimab in Patients With Solid Tumors

View source ↗

Summary

Expanded access update on cemiplimab for patients with solid tumors, including non-small cell lung cancer, basal cell carcinoma, and cutaneous squamous cell car…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma
• Cutaneous Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Cemiplimab (Libtayo) (cemiplimab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Non-Small Cell Lung Cancer (NSCLC), Basal Cell Carcinoma (BCC) | Status: APPROVED_FOR_MARKETING